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Intractableepilepsywithpainfulpartialmotorseizuresisarelativelyrareanddiﬃcultdisordertotreat.Weevaluatedtheusefulness
of botulinum toxin to reduce ictal pain. Two patients received two or four botulinum toxin (BTX) injections at one-to-two-month
intervals. Patient 1 had painful seizures of the right arm and hand. Patient 2 had painful seizures involving the left foot and
leg. Injections were discontinued after improved seizure control following resective surgery. Both patients received signiﬁcant
pain relief from the injections with analgesia lasting at least two months. Seizure severity was reduced, but seizure frequency and
duration were unaﬀected. For these patients, BTX was eﬀective in temporarily relieving pain associated with muscle contraction
in simple partial motor seizures. Our ﬁndings do not support the hypothesis that modulation of motor end-organ feedback aﬀects
focal seizure generation. BTX is a safe and reversible treatment that should be considered as part of adjunctive therapy after failure
to achieve control of painful partial motor seizures.
1.Introduction
Medically resistant epilepsy with frequent, painful simple
partial motor seizures is a relatively rare and diﬃcult
disorder to treat. If the pain is related to extreme muscle
contraction, then botulinum toxin (BTX) may be a useful
treatment for pain reduction. Eisenschenk and colleagues
[1] administered frontotemporal muscle BTX injections
duringvideoscalpEEGmonitoringandreportedareduction
in EMG artifact that allowed them to accurately localize
electrographicseizureonset.Awaadandcolleagues[2]found
that BTX injection resulted in a dramatic reduction of
painful myoclonus with functional improvement in limb
movement and ambulation. Lagueny and colleagues [3]
found BTX useful in treating stimulus-sensitive spinal seg-
mental myoclonus. In contrast, Tarsy and Schachter [4]
found no improvement in myoclonus or motor function in
patients with epilepsia partialis continua. In this report we
describe the use of BTX to control severe pain experienced
by two patients during simple partial motor seizures.
2. Patient 1
2.1. Clinical Background. A 70-year-old, right-handed male
developed simple motor seizures characterized by painful
dystonic posturing of the right hand following left pari-
etal meningeoma resection. Infrequently, the motor seizure
spread to the right face and leg. At baseline the patient
had a right hemiparesis with clasp knife rigidity of the
arm, hyperreﬂexia, an extensor plantar response, and distal
sensorylossintherightarmandlegpredominantlyinvolving
proprioception. Gait was consistent with mild right-sided
spastic hemiplegia. The patient’s use of his right hand was
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2.2. Pain Associated with Seizures. During seizures, the
strength and duration of muscle contraction appeared to
be proportional to pain intensity. At the onset, sustained
contraction of the right forearm and hand muscles with
dystonic posturing were associated with severe pain in the
righthandandwrist.Thepatientusuallyattemptedtorelieve
pain by passively dorsiﬂexing the right wrist and ﬁngers
with the left hand. Pain intensity was reported as 10/10 and
associatedwithgrimacing,moaning,andtearfulness.Seizure
involvement of the right face and right leg was not painful.
2.3.ContinuousVideo/ScalpEEGMonitoringandNeuroimag-
ing. Thirteen partial motor seizures were recorded during
inpatient, continuous video/EEG monitoring. Most were not
associated with epileptiform activity and either showed little
change or irregular left central theta waves. Rarely, rhythmic
low amplitude sharp waves appeared in the left central head
regionaftertheonsetofarmjerking.MRIscanningindicated
volume loss and increased T2 signal in the left parietal area.
2.4. Treatment: Vagus Nerve Stimulation (VNS) and Botox
Injection. Initially, VNS plus levetiracetam resulted in a 70%
reduction in seizure frequency. The VNS was turned oﬀ
to allow MRI scanning, and its initial eﬀectiveness was
never reestablished. The patient received four BTX injections
spaced1 to 2 monthsapart usingthe followingdosing sched-
ule:(1)200units,rightforearm,(2)50units,rightdeltoid;50
units, right biceps brachii, (3) 100 units, right forearm ﬂexor
muscles, and (4) 50 units, right deltoid; 50 units, right biceps
brachii;50unitsrightforearmﬂexors;50units,rightforearm
extensors.Thepatientreportedsatisfactorypainreliefduring
seizures and ictal facial grimacing and tearfulness resolved.
Epilepsy surgery was then performed and resulted in seizure
control so that further injections were not necessary.
2.5. Results. The patient reported less-painful seizures sev-
eral hours after the ﬁrst injection, suggesting an early onset
of toxin-induced analgesia or placebo eﬀect. However, he
reported the same degree of sustained relief (80–90%) prior
to injections two, three, and four as he did at one week
after ﬁrst injection. Thus, pain did not return to baseline
levelsbetweeninjections, sodurationofeﬀectfollowingeach
injection was at least two months. Pain during seizures was
easily tolerated by the patient but continued to vary directly
with seizure duration and intensity. Deﬁnitive resective
surgery occurred one month after the fourth injection.
3. Patient 2
3.1. Clinical Background. A 30-year-old male presented with
a 27-year history of partial motor seizures with painful
muscle contractions beginning in the left foot and leg,
sometimes spreading to the left thigh. The contractions
occasionally extended rostrally to the thoracic paraspinal
muscles. He also experienced complex partial, secondarily
generalized seizures and simple partial status epilepticus. His
neurological exam was normal.
Pain Associated with Seizures. The patient reported a pain
level of 10/10 during contractions of the left leg and foot at
seizure onset. Muscle contractions in the left thigh, as well as
in the paraspinal region, elicited a similar pain rating.
3.2.ContinuousVideo/ScalpEEGMonitoringandNeuroimag-
ing. Inpatient, continuous video/EEG monitoring recorded
10–50 partial motor seizures per day and an episode of
simple partial focal motor status. Electrographic seizure
onset appeared as rhythmic fast activity, C4 greater than
Cz, and 2–5 seconds after clinical seizure onset. The MRI
did not reveal structural abnormalities. Ictal SPECT did
not show perfusion abnormalities. Interictal PET revealed
hypometabolism in the medial right posterior frontal and
anterior parietal lobes.
3.3. Treatment: Vagus Nerve Stimulation (VNS) and Botox
Injection. While under our care, VNS plus phenytoin, oxcar-
bazepine, clorazepate, and levetiracetam failed to control
seizures. The patient received two BTX injections one month
apart: (1) 40 units, left gastrocnemius; 30 units, left tibialis
posterior; 30 units, left peroneus longus; 20 units, left
peroneus brevis; 20 units, left ﬂexor digitorum brevis; 40
units, left paraspinal muscles; 30 units, right paraspinal
muscles,and(2)300unitstotheleftthighmuscles,including
the vastus medialis, vastus lateralis, rectus femoris, and thigh
adductors. Injections were discontinued following successful
palliative epilepsy surgery. Surgery included subpial transec-
tions of the superior and medial aspects of the right cerebral
hemisphere and cortical resection of the medial aspect of the
right cerebral hemisphere. Because some seizures persisted,
the patient was subsequently enrolled by us (B. J. Fisch and
M. E. Carey) in a Phase II clinical trial for the treatment of
medically refractory partial seizures.
3.4. Results. The patient reported a 60–70% reduction in
pain in his left lower leg and paraspinal muscles during
seizures two to three days after his ﬁrst injection. The focus
of maximum pain shifted to the left foot and thigh but
the highest ictal pain rating was 4/10. The second injection
included left thigh muscles, and further pain relief was
reported.Toxin-inducedanalgesiaintheareastargetedbythe
ﬁrst injection was sustained for at least two months. Epilepsy
surgery occurred one month after the second injection.
4. Discussion
Our patients experienced substantial relief from painful
simple partial motor seizures following BTX injection. They
also reported persistent pain in the untreated muscles
after the ﬁrst injection and requested injections in those
muscle groups during subsequent treatments. When BTX
was injected into these previously untargeted locations, there
was further alleviation of pain. Neither patient missed a
BTX appointment and BTX therapy ceased only because
Patient1underwentsuccessfulepilepsysurgeryandPatient2
had an epilepsy surgery resulting in improvement in seizureCase Reports in Medicine 3
frequency and intensity and was then enrolled in a clinical
trial.
The frequency of seizures was not improved following
BTX injection in either patient. Our ﬁndings are therefore
in agreement with those of Tarsy and Schachter [4]w h o
reported BTX treatment to be ineﬀective for reducing
seizure frequency in epilepsia partialis continua. Conse-
quently, even though BTX made the seizures more tolerable
for our patients, both remained enthusiastic about trying
other means of seizure control, including epilepsy surgery.
Although biofeedback has been considered as a possible
treatment for some forms of epilepsy [5], in this speciﬁc
instance we found no evidence that the modulation of the
motor end organ aﬀects ictogenesis.
Most patients with painful muscle disorders experience
some relief after treatment with BTX [6]. The mechanism
of induced pain relief was initially attributed to muscle
paralysis;however,therearereportsinwhichBTX-associated
painreductionisoutofproportiontothedegreeofreduction
inmusclerelaxation,aswellasreportsofreliefinareaswhere
there was no reduction in muscle tension [7]. These clinical
observations raise the possibility that BTX-induced analgesia
may involve mechanisms that are not limited to the toxin’s
paralyzing eﬀect on skeletal muscle. It has been shown that
BTX undergoes retrograde transport to the dorsal root and
spinal cord [8], suggesting that BTX may be involved in
pain modulation at the spinal cord level. BTX has also been
shown to inhibit the release of substance P from trigeminal
nerve endings, block glutamate release, and interfere with
Fos expression in the periphery, in addition to its well-
knowneﬀectofinhibitingacetylcholinerelease[9,10].These
ﬁndings may help explain the rapid pain response to BTX
that occurred in our patients.
Pain is not a common manifestation of seizures. True
ictal pain in the absence of muscle contraction has been
documented [11], and one of us B. J. Fisch has treated a
patient with laboratory documented, simple partial seizures
consisting of an extremely painful, unilateral burning foot
sensation. Pain related to muscle contraction during seizure
is more common, albeit rare. Overall seizure control remains
the primary goal for treatment of painful motor seizures, as
it is for any type of seizure disorder. However, when seizures
are refractory to aggressive traditional treatment, additional
symptomatic relief should be explored.
BTX is a safe option for symptomatic relief and for
pain in particular [12], and, most importantly, its eﬀects are
typically reversible (e.g., [13]). Eisenschenk and colleagues
reported no adverse eﬀectsin their account of 3 patients with
BTX-A injections into the frontotemporal muscles prior to
inpatient monitoring to reduce muscle artifact and improve
seizure localization using EEG. Full recovery of muscle
strength occurred in an average of 11.3 weeks [1]. Other
studies targeting larger muscle groups have also reported
few or no adverse eﬀects. For example, in a study of 39
adolescents and adults, BTX injections were administered to
the upper and lower extremities to treat acquired spasticity.
The authors report no adverse eﬀects throughout treatment
[14]. In a randomized, double-blinded, controlled compar-
ison of BTX and Neuronox for spastic equines gait with
cerebral palsy, Kim and colleagues injected the calf muscles
of children (BTX, n = 59; Neuronox, n = 60) and followed
them for 24 weeks. Frequency of adverse eﬀects did not
diﬀer between the treatment groups, and there was only
one participant receiving BTX that experienced transient
subjective muscle weakness [15]. Finally, a meta-analysis of
randomized, placebocontrolled, double-blind trials of BTX
in poststroke spasticity showed that there was no diﬀerence
in the odds ratio of having an adverse eﬀect between placebo
and BTX treatment groups [16].
Our limited experience using BTX to reduce pain related
to muscle contraction during seizure suggests that BTX
may be an eﬀective treatment. It remains unknown whether
BTX injections would have any eﬀect on localized ictal pain
unassociated with muscle contraction. Future, prospective
controlled studies of BTX for painful motor seizures are
requiredtodeterminethetrueclinicalutilityofthispalliative
intervention. The safety and reversibility of BTX, coupled
with its documented eﬀects of alleviating pain, make it a
feasible option for adjunctive, palliative treatment of painful
motor seizures.
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